Retro Biosciences takes a portfolio approach to aging biology that's unusual for a company this young: rather than committing to one mechanism, it runs parallel research programs across autophagy (the cell's internal recycling and cleanup process), plasma-derived interventions inspired by parabiosis research (the finding that young blood factors can rejuvenate old tissue in animal models), and partial cellular reprogramming, the same broad category Altos Labs is working in.
The company's founding and funding, backed publicly by OpenAI's Sam Altman, has made it one of the more closely watched names in longevity biotech, partly for the science and partly for what it signals: a wave of technology-sector capital treating biological aging as a tractable engineering problem rather than an inevitability. Whether that framing holds up against the genuine difficulty of human aging biology is still an open question the company's own results will have to answer.
Running multiple mechanistic bets in parallel, rather than a single therapeutic thesis, is itself a data-and-compute-intensive strategy, one where AI-assisted research infrastructure (screening candidate interventions, modeling which combinations are worth pursuing) plays a growing role. See the cellular reprogramming entry for more on that specific mechanism, and the AI drug discovery article for how AI is reshaping which of these parallel bets get prioritized.